Vaccines from China’s Kexing
China’s push for “vaccine diplomacy” has allowed Kexing and Sinopharm’s vaccines to go overseas, but the safety of domestic vaccines has been questioned by various sectors. A recent report shows that even Chinese healthcare workers who need priority vaccination are reluctant to receive domestic vaccines due to concerns about side effects or questions about effectiveness, highlighting the distrust of Chinese healthcare workers and the highly educated population towards domestic vaccines.
According to Punch News, the China Center for Disease Control and Prevention recently released a survey on the willingness of health care workers in Zhejiang Province to receive vaccines against the Chinese Communist Party virus. The survey was published in China Vaccines and Immunization, a journal affiliated with the Chinese Center for Disease Control and Prevention. The authors are from the CDC and Zhejiang Province CDC, and include Gao Fu, the often-active director of the CDC.
The survey collected self-reported information through an online questionnaire from September to October last year from 756 medical and CDC staff at the Zhejiang, city and county levels, of whom more than 70% were from urban or suburban areas and less than 30% were from rural areas; 3.31%, 77.78% and 18.91% had secondary school and below, college or university, and master’s degree and above, respectively.
Emergency vaccination against the CCP virus was launched in many parts of Zhejiang Province last October, making it one of the first provinces in China to implement emergency vaccination on a large scale.
The survey shows that for emergency use of the vaccine, 42.46% of the public is willing to be vaccinated; while for post-marketing use of the vaccine, 27.65% are willing to be vaccinated, which is significantly lower than the general public’s willingness of about 90% to be vaccinated.
The report said that the high willingness to vaccinate for emergency use than for post-marketing use is due to the fact that the former is promoted by government organizations, while the latter is a voluntary choice.
The report points out that for those groups who are unwilling to be vaccinated, the main concern is the fear of vaccine side effects (57.69%), followed by doubts about the effectiveness of the vaccine (34.14%), the belief that there are no more local cases to be vaccinated (29.81%), the need to charge for the vaccine (24.52%) and the inconvenience of vaccination at community health centers (8.66%), respectively.
Among the emergency use of vaccines, the willingness to vaccinate was low among women, those with a master’s degree or higher, and medical personnel. This is analyzed to be related to the fact that highly educated groups receive more information on social networks and have more concerns about vaccine effectiveness and side effects.
In the past few years, China has repeatedly been exposed to faulty and tainted vaccines, causing the Chinese public to turn away from domestic vaccines. Last December, Chinese Communist authorities mobilized and tested domestic vaccines for mapping. Professor Zhang Wenhong, a leading Chinese Epidemic prevention expert and director of the Infection Department at Huashan Hospital of Fudan University in Shanghai, said at a conference, “Whether you have 10% vaccination or 20% vaccination, actually we are not in a hurry.” He also said, “So who is going to should fight first today? I personally feel that it is the leading cadres who should play first now”.
Since then, the Internet has been full of calls to “let the leaders fight first”. The Voice of America, citing overseas Chinese media, reported that none of the local Communist Party officials had signed up for the emergency vaccination mapping notice in Zhenjiang, Jiangsu province. A similar emergency mapping in Shanghai in November showed that health care workers were reluctant to be vaccinated, with more than 90 percent of health care workers at Yangpu District Hospital of Traditional Chinese Medicine refusing to get the vaccine. None of the Communist Party’s leaders have been publicly vaccinated with the domestic vaccine either.
In addition to mainland China, Hong Kong received 100 doses of Kratom vaccine from China’s Kexing Bio on February 19 for emergency administration. However, health care workers, who are a priority for vaccination in Hong Kong, were not very willing to receive the vaccine. According to Apple Daily, Yu Wai-ming, chairman of the HA Staff Front, said union members have a wait-and-see attitude and do not intend to be the first batch of vaccinators, and said the government has lowered the criteria for approving the Kexing vaccine, causing the public to lose confidence.
Hong Kong Land Passenger and Freight Transport Industry Council Chairman Chiang Chi-wai said that nearly 40% of cross-border drivers in Hong Kong are now over 60 years of age, and older drivers are worried about the side effects of the vaccine, hoping that the government will increase transparency and explain whether the non-vaccination will affect the cross-border work of drivers.
Kexing vaccine so far only one, two phase clinical data published in international medical journals, three phase data has not been published. It is generally believed that before the vaccine is officially used, its phase III data must be published in international medical journals The Kexing vaccine has so far only phase I and II clinical data published in international medical journals, and phase III data has not yet been published. It is generally believed that Phase III data must be published in international medical journals before the vaccine can be officially used.
Many people have been infected abroad even after receiving the CCP vaccine
Currently, developed countries commonly purchase vaccines developed by well-known pharmaceutical companies such as Pfizer, BNT, Modena, Oxford, etc. In addition to vaccination within China, Kexing and Sinopharm vaccines are currently sold to Hong Kong, Macau, the Philippines, Thailand, Indonesia, Malaysia, Brazil, Ukraine, Serbia, Hungary, Peru, and Egypt.
According to data provided by London-based consultancy Airfinity, as of mid-November this year, AstraZeneca (AstraZeneca) had pre-ordered 2.4 billion doses, Pfizer (Pfizer) had ordered about 1 billion doses, while China’s Kexing (Sinovac) and Sinopharm (Sinopharm) had less than 500 million doses scheduled in total, of which most of which are from countries participating in clinical trials.
Some of these countries are in litigation with either Kexing or Sinopharm. In other countries, there are reports of Chinese people who were given the vaccine and went to work in foreign countries and still contracted the disease.
Last December, Radio Free Asia reported that at least 17 Chinese were infected with the Chinese Communist Party virus in Angola, 16 of them from a Chinese-owned state-owned enterprise in Lunda Norte province. According to sources, the workers were given a vaccine developed by Sinopharm before they left the country.
Recent Comments